FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb
The FDA has accepted a supplemental application for OPDUALAG, a combination of nivolumab and relatlimab-rmbw.
Company
Pharmaceutical intelligence for Bristol Myers Squibb with 21 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.